SABR radiation for kidney cancer that has spread
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether a precise, high-dose radiation treatment (SABR) can safely control kidney cancer that has spread to a few spots in the body. It may be an option if your cancer is progressing during treatment and your spots can be safely targeted with radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have kidney cancer that has spread to other parts of the body (metastatic), either newly diagnosed or growing during treatment.
- You are 18 years or older.
- You are able to take care of yourself (ECOG score 0-3, meaning you are up and about at least half the day).
- A radiation doctor has confirmed that all your cancer spots can safely receive a very high, precise dose of radiation (SABR).
- You are able to receive standard drug therapy for kidney cancer (targeted therapy or immunotherapy combination).
- There is no prior history of radiation therapy to the same cancer spots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a higher radiation dose to some tumors can help control kidney cancer that has spread to other parts of the body. It is for people who cannot have surgery to remove these tumors and are already receiving other treatments.
This trial tests a precise type of radiation called stereotactic body proton therapy for people with kidney cancer who cannot have surgery or other local treatments. It aims to see if this focused radiation can control the tumor with fewer side effects.
This trial tests a focused, high-dose radiation treatment (SABR) for kidney tumors that are too risky to remove with surgery or where surgery was declined. It may help shrink the tumor while limiting damage to surrounding tissue.
This trial tests combining a precise type of radiation (SABR) with standard targeted therapy and immunotherapy drugs for kidney cancer that has come back or spread. The goal is to see if adding radiation improves outcomes.
This trial tests whether targeted, high-precision radiation (stereotactic radiotherapy) can control a small number of growing kidney cancer metastases while you continue systemic treatment. It may help people who have “oligoprogressive” disease, where only 1–3 spots are getting worse.
This trial compares standard systemic therapy (medication) alone versus systemic therapy plus targeted radiation to the cancer spots for people with kidney cancer that has spread to a limited number of places (up to 5 spots). It aims to see if adding radiation helps control the cancer better.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.